Anti-Vinculin antibody [VIN-54] (ab130007)

Submit a review Submit a question References (2)

Overview

  • Product name

    Anti-Vinculin antibody [VIN-54]
    See all Vinculin primary antibodies

  • Description

    Mouse monoclonal [VIN-54] to Vinculin

  • Host species

    Mouse

  • Tested applications

    Suitable for: ICC/IF, WB, IHC-P, IHC-Frmore details

  • Species reactivity

    Reacts with: Mouse, Rat, Chicken, Human, Monkey

  • Immunogen

    Human Vinculin purified from uterus.

  • Positive control

    • WB: Hela, HepG2, Cos-7, U-87 MG, PC-12, RH35, HEPA1-6 and NIH-3T3 whole cell lysates; ICC/IF: Human mammary cancer cells; IHC-P: Human breast tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab130007 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 2 µg/ml.
WB Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 124 kDa.
IHC-P Use a concentration of 2 - 4 µg/ml.
IHC-Fr Use a concentration of 2 - 4 µg/ml.

Target

  • Function

    Actin filament (F-actin)-binding protein involved in cell-matrix adhesion and cell-cell adhesion. Regulates cell-surface E-cadherin expression and potentiates mechanosensing by the E-cadherin complex. May also play important roles in cell morphology and locomotion.

  • Tissue specificity

    Metavinculin is muscle-specific.

  • Involvement in disease

    Defects in VCL are the cause of cardiomyopathy dilated type 1W (CMD1W) [MIM:611407]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
    Defects in VCL are the cause of cardiomyopathy familial hypertrophic type 15 (CMH15) [MIM:613255]. It is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

  • Sequence similarities

    Belongs to the vinculin/alpha-catenin family.

  • Domain

    Exists in at least two conformations. When in the closed, 'inactive' conformation, extensive interactions between the head and tail domains prevent detectable binding to most of its ligands. It takes on an 'active' conformation after cooperative and simultaneous binding of two different ligands. This activation involves displacement of the head-tail interactions and leads to a significant accumulation of ternary complexes. The active form then binds a number of proteins that have both signaling and structural roles that are essential for cell adhesion.
    The N-terminal globular head (Vh) comprises of subdomains D1-D4. The C-terminal tail (Vt) binds F-actin and cross-links actin filaments into bundles. An intramolecular interaction between Vh and Vt masks the F-actin-binding domain located in Vt. The binding of talin and alpha-actinin to the D1 subdomain of vinculin induces a helical bundle conversion of this subdomain, leading to the disruption of the intramolecular interaction and the exposure of the cryptic F-actin-binding domain of Vt. Vt inhibits actin filament barbed end elongation without affecting the critical concentration of actin assembly.

  • Post-translational
    modifications

    Phosphorylated; on serines, threonines and tyrosines. Phosphorylation on Tyr-1133 in activated platelets affects head-tail interactions and cell spreading but has no effect on actin binding nor on localization to focal adhesion plaques.
    Aceylated; mainly by myristic acid but also small amount of palmitic acid.

  • Cellular localization

    Cytoplasm > cytoskeleton. Cell junction > adherens junction. Cell membrane. Cytoplasmic face of adhesion plaques. Recruitment to cell-cell junctions occurs in a myosin II-dependent manner. Interaction with CTNNB1 is necessary for its localization to the cell-cell junctions.
  • Information by UniProt

  • Database links

    see all

  • Alternative names

    • CMD1W antibody
    • CMH15 antibody
    • Epididymis luminal protein 114 antibody
    • HEL114 antibody
    • Metavinculin antibody
    • MV antibody
    • MVCL antibody
    • OTTHUMP00000019861 antibody
    • OTTHUMP00000019862 antibody
    • VCL antibody
    • VINC antibody
    • VINC_HUMAN antibody
    • Vinculin antibody
    see all

Images

  • Western blot - Anti-Vinculin antibody [VIN-54] (ab130007)
    Western blot - Anti-Vinculin antibody [VIN-54] (ab130007)
    All lanes : Anti-Vinculin antibody [VIN-54] (ab130007) at 0.5 µg/ml

    Lane 1 : Hela whole cell lysates
    Lane 2 : HepG2 whole cell lysates
    Lane 3 : Monkey COS-7 whole cell lysates
    Lane 4 : U-87MG whole cell lysates
    Lane 5 : Rat PC-12 whole cell lysates
    Lane 6 : Rat RH35 whole cell lysates
    Lane 7 : Mouse HEPA1-6 whole cell lysates
    Lane 8 : Mouse NIH3T3 whole cell lysates

    Lysates/proteins at 50 µg per lane.

    Secondary
    All lanes : Goat anti- mouse IgG-HRP at 1/10000 dilution

    Developed using the ECL technique.

    Predicted band size: 124 kDa
    Observed band size: 124 kDa



    The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit with Tanon 5200 system.

    After Electrophoresis, proteins were transferred to a Nitrocellulose membrane at 150mA for 50-90 minutes. Blocked the membrane with 5% Non-fat Milk/ TBS for 1.5 hour at RT.

     

     

     

  • Immunohistochemistry (Frozen sections) - Anti-Vinculin antibody [VIN-54] (ab130007)
    Immunohistochemistry (Frozen sections) - Anti-Vinculin antibody [VIN-54] (ab130007)

    Immunohistochemical analysis of frozen sections of human placenta tissue labelling Vinculin with ab130007 at 1μg/ml, followed by a biotinylated goat anti-mouse IgG secondary antibody. The tissue was blocked with 10% goat serum. The tissue section was developed using Strepavidin-Biotin-Complex with DAB as the chromogen.

  • Immunocytochemistry/ Immunofluorescence - Anti-Vinculin antibody [VIN-54] (ab130007)
    Immunocytochemistry/ Immunofluorescence - Anti-Vinculin antibody [VIN-54] (ab130007)

    Immunocytochemistry/Immunofluorescent analysis of human mammary cancer cells labelling Vinculin with ab130007 at 2μg/ml, followed by a DyLight®488 Conjugated Goat Anti-Mouse secondary antibody at 1/100 dilution. DAPI was used as a nuclear counterstain.

     

  • Immunohistochemistry (Frozen sections) - Anti-Vinculin antibody [VIN-54] (ab130007)
    Immunohistochemistry (Frozen sections) - Anti-Vinculin antibody [VIN-54] (ab130007)

    Immunohistochemical analysis of frozen sections of human placenta tissue labelling Vinculin with ab130007 at 1μg/ml, followed by a biotinylated goat anti-mouse IgG secondary antibody. The tissue was blocked with 10% goat serum. The tissue section was developed using Strepavidin-Biotin-Complex with DAB as the chromogen.

  • Western blot - Anti-Vinculin antibody [VIN-54] (ab130007)
    Western blot - Anti-Vinculin antibody [VIN-54] (ab130007)
    All lanes : Anti-Vinculin antibody [VIN-54] (ab130007) at 1/10000 dilution

    Lane 1 : HAP1
    Lane 2 : HEK293
    Lane 3 : U-2 OS

    Lysates/proteins at 20 µg per lane.

    Performed under reducing conditions.

    Predicted band size: 124 kDa



    ab130007 was shown to recognize vinculin when whole cell lysates were subjected to SDS-PAGE. The blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes which was incubated overnight at 4°C at 0.1 μg antibody per mL and developed with Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibody at 1/15000 dilution for 1 hour at room temperature before imaging.

References

This product has been referenced in:

  • Pillai-Kastoori L  et al. Antibody validation for Western blot: By the user, for the user. J Biol Chem 295:926-939 (2020). Read more (PubMed: 31819006) »
  • Demircioglu FE  et al. The AAA?+?ATPase TorsinA polymerizes into hollow helical tubes with 8.5 subunits per turn. Nat Commun 10:3262 (2019). Read more (PubMed: 31332180) »
See all 2 Publications for this product

Publishing research using ab130007? Please let us know so that we can cite the reference in this datasheet.

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

There are currently no Customer reviews or Questions for ab130007.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com